Manifold Biotechnologies has filed a notice of an exempt offering of securities to raise $32,784,801.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Manifold Biotechnologies is raising up to $32,784,801.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Manifold Biotechnologies
Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the worlds first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. Weve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. Were growing and were looking for those who are excited about the potential of our novel approach to engineering biology.
To learn more about Manifold Biotechnologies, visit http://manifold.bio/
Manifold Biotechnologies Linkedin Page: https://www.linkedin.com/company/manifold-bio/
Contact:
Gleb Kuznetsov, Chief Executive Officer
801-244-4494
https://www.linkedin.com/in/gleb-kuznetsov/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.